Evidence map›Paper›PMID 35576119›Full record

ArticleMolecular oral microbiology2022

Interleukin-34 permits Porphyromonas gingivalis survival and NF-κB p65 inhibition in macrophages.

Ammar Almarghlani, Rajendra P Settem, Andrew J Croft, Sarah Metcalfe, Matthew Giangreco, Jason G Kay

Open access · greenAbstract read
In one paragraph

Article in Molecular oral microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. The oral-gut-circulatory axis: from homeostasis to colon cancer.Frontiers in cellular and infection microbiology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ammar AlmarghlaniDepartment of Oral Biology, School of Dental Medicine, University at Buffalo, Buffalo, New York, USA.
Rajendra P SettemDepartment of Oral Biology, School of Dental Medicine, University at Buffalo, Buffalo, New York, USA.ORCID 0000-0002-3577-7675
Andrew J CroftDepartment of Oral Biology, School of Dental Medicine, University at Buffalo, Buffalo, New York, USA.
Sarah MetcalfeDepartment of Oral Biology, School of Dental Medicine, University at Buffalo, Buffalo, New York, USA.
Matthew GiangrecoDepartment of Oral Biology, School of Dental Medicine, University at Buffalo, Buffalo, New York, USA.
Jason G KayDepartment of Oral Biology, School of Dental Medicine, University at Buffalo, Buffalo, New York, USA.ORCID 0000-0001-8944-6612
University at Buffalo, State University of New York · US

Funding

Advanced Training in Oral BiologyT32DE023526 · NIDCR · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI Stefan Hans-Klaus Ruhl · 2013 to 2026
$3.7M
A role for immune cell plasticity in commensal survival and escalation of inflammationR01DE028307 · NIDCR · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI KAY, JASON G · 2020 to 2024
$1.9M
Spinning disk confocal microscopeS10OD025204 · OD · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI KAY, JASON G · 2019 to 2019
$488k
Mechanisms of Streptococcus gordonii survival within phagocytesR03DE025062 · NIDCR · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI KAY, JASON G · 2016 to 2017
$239k
Mechanisms of Oral Streptococcus Macrophage ActivationF31DE029400 · NIDCR · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI METCALFE, SARAH LUCILE · 2019 to 2021
$94k
NIDCR NIH HHS F31 DE029400NIDCR NIH HHS R01 DE028307NIDCR NIH HHS R03 DE025062NIDCR NIH HHS T32 DE023526NIH HHS S10 OD025204
6 · The paper itself

Abstract

Interleukin-34 (IL-34) is a cytokine that supports the viability and differentiation of macrophages. An important cytokine for the development of epidermal immunity, IL-34, is present and plays a role in the immunity of the oral environment. IL-34 has been linked to inflammatory periodontal diseases, which involve innate phagocytes, including macrophages. Whether IL-34 can alter the ability of macrophages to effectively interact with oral microbes is currently unclear. Using macrophages derived from human blood monocytes with either the canonical cytokine colony-stimulating factor (CSF)1 or IL-34, we compared the ability of the macrophages to phagocytose, kill, and respond through the production of cytokines to the periodontal keystone pathogen Porphyromonas gingivalis. While macrophages derived from both cytokines were able to engulf the bacterium equally, IL-34-derived macrophages were much less capable of killing internalized P. gingivalis. Of the macrophage cell surface receptors known to interact with P. gingivalis, dendritic cell-specific intercellular adhesion molecule-grabbing nonintegrin was found to have the largest variation between IL-34- and CSF1-derived macrophages. We also found that upon interaction with P. gingivalis, IL-34-derived macrophages produced significantly less of the neutrophil chemotactic factor IL-8 than macrophages derived in the presence of CSF1. Mechanistically, we identified that the levels of IL-8 corresponded with P. gingivalis survival and dephosphorylation of the major transcription factor NF-κB p65. Overall, we found that macrophages differentiated in the presence of IL-34, a dominant cytokine in the oral gingiva, have a reduced ability to kill the keystone pathogen P. gingivalis and may be susceptible to specific bacteria-mediated cytokine modification.

Indexed as

Interleukin-8Porphyromonas gingivalisBacteroidaceae InfectionsGingivaGingival DiseasesHumansInterleukinsMacrophagesNF-kappa BIL34 protein, humanInterleukin-8InterleukinsNF-kappa BDC-SIGNinterleukin-34interleukin-8periodontal diseasephagocytosis

Identifiers

PMID35576119
PMCPMC9617590
OpenAlexW4280615992

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.